Hood River Capital Management LLC Has $13,073,000 Stake in PRA Health Sciences Inc. (PRAH)
Hood River Capital Management LLC lowered its position in shares of PRA Health Sciences Inc. (NASDAQ:PRAH) by 12.1% during the second quarter, Holdings Channel reports. The fund owned 313,062 shares of the company’s stock after selling 43,065 shares during the period. PRA Health Sciences makes up approximately 1.7% of Hood River Capital Management LLC’s portfolio, making the stock its 19th largest position. Hood River Capital Management LLC’s holdings in PRA Health Sciences were worth $13,073,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PRAH. A.R.T. Advisors LLC acquired a new position in PRA Health Sciences during the first quarter worth approximately $1,232,000. Legal & General Group Plc raised its position in PRA Health Sciences by 38.0% in the first quarter. Legal & General Group Plc now owns 4,903 shares of the company’s stock worth $211,000 after buying an additional 1,350 shares during the last quarter. Bayesian Capital Management LP acquired a new position in PRA Health Sciences during the first quarter worth approximately $206,000. HBK Investments L P acquired a new position in PRA Health Sciences during the first quarter worth approximately $295,000. Finally, AXA acquired a new position in PRA Health Sciences during the first quarter worth approximately $436,000.
PRA Health Sciences Inc. (NASDAQ:PRAH) traded down 0.02% during mid-day trading on Wednesday, hitting $56.71. The company had a trading volume of 336,449 shares. The company has a 50 day moving average of $52.81 and a 200 day moving average of $47.35. PRA Health Sciences Inc. has a 1-year low of $33.00 and a 1-year high of $57.24. The firm has a market capitalization of $3.46 billion, a PE ratio of 48.64 and a beta of 0.53.
PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Thursday, July 28th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.04. PRA Health Sciences had a return on equity of 20.47% and a net margin of 4.53%. The business earned $394.20 million during the quarter, compared to analyst estimates of $381.25 million. During the same quarter in the previous year, the business earned $0.47 earnings per share. The company’s revenue for the quarter was up 16.0% compared to the same quarter last year. Analysts predict that PRA Health Sciences Inc. will post $2.47 earnings per share for the current fiscal year.
A number of research analysts have commented on the company. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $65.00 price target for the company in a research report on Wednesday. Citigroup Inc. increased their target price on PRA Health Sciences from $55.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Jefferies Group reissued a “buy” rating on shares of PRA Health Sciences in a research report on Tuesday, September 13th. KeyCorp raised PRA Health Sciences from a “sector weight” rating to an “overweight” rating and set a $55.00 target price for the company in a research report on Monday, June 13th. Finally, First Analysis assumed coverage on PRA Health Sciences in a research report on Monday, June 20th. They issued an “equal weight” rating and a $47.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $51.61.
In other PRA Health Sciences news, CEO Colin Shannon sold 113,133 shares of the business’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $51.57, for a total transaction of $5,834,268.81. Following the completion of the transaction, the chief executive officer now owns 120,000 shares in the company, valued at $6,188,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP David W. Dockhorn sold 107,257 shares of the business’s stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $49.00, for a total value of $5,255,593.00. The disclosure for this sale can be found here. Company insiders own 2.50% of the company’s stock.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc. (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.